These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 16144017)
1. Polymer-based paclitaxel-eluting stent for treatment of chronic total occlusions of native coronaries: results of a Taxus CTO registry. Buellesfeld L; Gerckens U; Mueller R; Schmidt T; Grube E Catheter Cardiovasc Interv; 2005 Oct; 66(2):173-7. PubMed ID: 16144017 [TBL] [Abstract][Full Text] [Related]
2. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I. Büllesfeld L; Gerckens U; Müller R; Grube E Z Kardiol; 2003 Oct; 92(10):825-32. PubMed ID: 14579046 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW; J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247 [TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME; Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586 [TBL] [Abstract][Full Text] [Related]
5. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. Krucoff MW; Kereiakes DJ; Petersen JL; Mehran R; Hasselblad V; Lansky AJ; Fitzgerald PJ; Garg J; Turco MA; Simonton CA; Verheye S; Dubois CL; Gammon R; Batchelor WB; O'Shaughnessy CD; Hermiller JB; Schofer J; Buchbinder M; Wijns W; J Am Coll Cardiol; 2008 Apr; 51(16):1543-52. PubMed ID: 18420096 [TBL] [Abstract][Full Text] [Related]
6. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Colombo A; Drzewiecki J; Banning A; Grube E; Hauptmann K; Silber S; Dudek D; Fort S; Schiele F; Zmudka K; Guagliumi G; Russell ME; Circulation; 2003 Aug; 108(7):788-94. PubMed ID: 12900339 [TBL] [Abstract][Full Text] [Related]
7. Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: a prospective multicenter registry. Buszman P; Trznadel S; Milewski K; Rzeźniczak J; Przewłocki T; Kośmider M; Wójcik J; Janczak J; Zurakowski A; Kondys M; Król M; Kinasz L; Jaklik A; Rzeszutko Ł; Kałuza GL; Kiesz S; Gil R Catheter Cardiovasc Interv; 2008 Jan; 71(1):51-7. PubMed ID: 18098182 [TBL] [Abstract][Full Text] [Related]
8. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Mehilli J; Kastrati A; Wessely R; Dibra A; Hausleiter J; Jaschke B; Dirschinger J; Schömig A; Circulation; 2006 Jan; 113(2):273-9. PubMed ID: 16391155 [TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL; Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853 [TBL] [Abstract][Full Text] [Related]
10. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME; Circulation; 2004 Apr; 109(16):1942-7. PubMed ID: 15078803 [TBL] [Abstract][Full Text] [Related]
11. Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions. Iofina E; Langenberg R; Blindt R; Kühl H; Kelm M; Hoffmann R Am J Cardiol; 2006 Oct; 98(8):1022-7. PubMed ID: 17027564 [TBL] [Abstract][Full Text] [Related]
12. Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation. A post hoc analysis of TAXUS II. Silber S; Hamburger J; Grube E; Pfisterer M; Belardi J; Webb J; Zmudka K; Nienaber C; Hauptman K; Rutsch W; Dawkins K; Drzewiecki J; Koglin J; Colombo A Herz; 2004 Mar; 29(2):171-80. PubMed ID: 15057438 [TBL] [Abstract][Full Text] [Related]
13. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066 [TBL] [Abstract][Full Text] [Related]
14. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Silber S; Colombo A; Banning AP; Hauptmann K; Drzewiecki J; Grube E; Dudek D; Baim DS Circulation; 2009 Oct; 120(15):1498-504. PubMed ID: 19786634 [TBL] [Abstract][Full Text] [Related]
16. Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Grube E; Silber S; Hauptmann KE; Buellesfeld L; Mueller R; Lim V; Gerckens U; Russell ME Am J Cardiol; 2005 Jul; 96(1):79-82. PubMed ID: 15979439 [TBL] [Abstract][Full Text] [Related]
17. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. Ellis SG; Popma JJ; Lasala JM; Koglin JJ; Cox DA; Hermiller J; O'shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Stone GW J Am Coll Cardiol; 2005 Apr; 45(8):1193-200. PubMed ID: 15837248 [TBL] [Abstract][Full Text] [Related]
18. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results. Liu HB; Xu B; Qiao SB; Yang YJ; Ma WH; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Li JJ; Chen JL; Gao RL Chin Med J (Engl); 2007 Apr; 120(7):574-7. PubMed ID: 17442205 [TBL] [Abstract][Full Text] [Related]
19. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. Lansky AJ; Costa RA; Mooney M; Midei MG; Lui HK; Strickland W; Mehran R; Leon MB; Russell ME; Ellis SG; Stone GW; J Am Coll Cardiol; 2005 Apr; 45(8):1180-5. PubMed ID: 15837246 [TBL] [Abstract][Full Text] [Related]
20. Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study. Bhargava B; Karthikeyan G; Shankar PB; Seth S; Singh S; Pr U; Lal AV; Mohanty M Indian Heart J; 2008; 60(3):228-32. PubMed ID: 19240312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]